PMID- 25035283
OWN - NLM
STAT- MEDLINE
DCOM- 20150608
LR  - 20211021
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Print)
IS  - 1558-7673 (Linking)
VI  - 12
IP  - 5
DP  - 2014 Oct
TI  - Current practices in the management of adverse events associated with targeted 
      therapies for advanced renal cell carcinoma: a national survey of oncologists.
PG  - 341-7
LID - S1558-7673(14)00079-2 [pii]
LID - 10.1016/j.clgc.2014.04.001 [doi]
AB  - BACKGROUND: Oncologists treating patients with targeted therapies encounter 
      adverse events (AEs) that pose management challenges, lead to dosing 
      inconsistencies, and impact patient quality of life. Oncologists' practices and 
      attitudes in the management of targeted therapy-related AEs in patients with 
      renal cell carcinoma (RCC) are poorly understood. We sought to identify unmet 
      needs associated with AE management and understand oncologists' treatment 
      optimization strategies. METHODS: A 24-item online survey was administered in 
      August 2012 to 119 US oncologists treating patients with advanced RCC. The survey 
      solicited responses regarding demographics, practice settings, AE management 
      practice patterns and beliefs, treatment barriers, and patient education. 
      RESULTS: Respondents indicated that between 25% and 50% of patients require dose 
      modification/discontinuation because of AEs. The greatest barrier to optimizing 
      treatment for RCC is the unpredictability of patient responses to treatment 
      (43%). Most respondents (78%) discuss AE management with patients, but only a 
      minority of them proactively reach out to patients (46%). Most practitioners 
      (70%) refer patients to nononcology specialists when faced with unfamiliar AEs, 
      although finding interested physicians (43%) and time constraints (40%) were the 
      most commonly cited barriers to consulting with other specialties. CONCLUSION: 
      Results suggest that many patients require dose modification/discontinuation 
      because of AEs and that nononcologists are a frequently utilized resource to 
      manage these events. There is a need for predictive drug toxicity markers to 
      establish counseling and prevention, along with opportunities for increased 
      education on supportive care techniques to maintain health-related quality of 
      life and consistent dosing.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Ruiz, Janelle Nicole
AU  - Ruiz JN
AD  - Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY; 
      Stanford School of Medicine, Stanford, CA.
FAU - Belum, Viswanath Reddy
AU  - Belum VR
AD  - Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Creel, Patricia
AU  - Creel P
AD  - Duke Cancer Institute, Duke University Medical Center, Durham, NC.
FAU - Cohn, Allen
AU  - Cohn A
AD  - Rocky Mountain Cancer Centers, Denver, CO.
FAU - Ewer, Michael
AU  - Ewer M
AD  - MD Anderson Cancer Center, Houston, TX.
FAU - Lacouture, Mario E
AU  - Lacouture ME
AD  - Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY. 
      Electronic address: lacoutum@mskcc.org.
LA  - eng
GR  - R25 CA020449/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140516
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Disease Management
MH  - Drug-Related Side Effects and Adverse Reactions/*therapy
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy
MH  - Molecular Targeted Therapy/adverse effects
MH  - Practice Patterns, Physicians'
MH  - Referral and Consultation/*statistics & numerical data
MH  - Surveys and Questionnaires
PMC - PMC4181324
MID - NIHMS618868
OTO - NOTNLM
OT  - Advanced kidney cancer
OT  - Anticancer therapy
OT  - Oncologist practice patterns
OT  - Side effect management practices
OT  - Targeted therapy-related side effects
COIS- Conflict of Interest Page: MEL has a consultant or advisory role with Advancell, 
      AstraZeneca, Aveo, Bayer, BergPharma, Bristol-Myers Squibb, Galderma, Genentech, 
      Genzyme, GlaxoSmithKline, Helsinn, Imclone, Lilly, LindiSkin, Merck, Novocure, 
      Onyx, Pfizer, Roche, Sandoz, Sanofi Aventis and Wyeth. PC, AC, and ME each have a 
      consultant role for Pfizer. JNR and VRB have nothing to disclose.
EDAT- 2014/07/19 06:00
MHDA- 2015/06/09 06:00
PMCR- 2015/10/01
CRDT- 2014/07/19 06:00
PHST- 2014/01/26 00:00 [received]
PHST- 2014/03/26 00:00 [revised]
PHST- 2014/04/03 00:00 [accepted]
PHST- 2014/07/19 06:00 [entrez]
PHST- 2014/07/19 06:00 [pubmed]
PHST- 2015/06/09 06:00 [medline]
PHST- 2015/10/01 00:00 [pmc-release]
AID - S1558-7673(14)00079-2 [pii]
AID - 10.1016/j.clgc.2014.04.001 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2014 Oct;12(5):341-7. doi: 10.1016/j.clgc.2014.04.001. 
      Epub 2014 May 16.